PMVP Profile
PMV Pharmaceuticals, Inc. is a leading precision oncology company dedicated to the discovery and development of innovative therapies targeting p53 mutations in cancer. The company specializes in creating small molecule treatments that address the genetic alterations associated with various cancers, focusing on tumor-agnostic approaches that can be applied across multiple cancer types. PMV Pharmaceuticals aims to restore normal p53 function, a critical tumor suppressor protein that is frequently mutated in cancers.
The company’s flagship product candidate, PC14586, is a novel small molecule designed to target and correct the p53 protein with the Y220C mutation, thereby restoring its wild-type function. This innovative therapy represents a significant advancement in cancer treatment by directly addressing the underlying genetic abnormalities that contribute to tumor progression. PMV Pharmaceuticals is also advancing several other programs targeting mutant p53 proteins, including those with the R282W and R273H mutations, as well as additional hotspot mutations. These programs aim to develop a comprehensive suite of therapies to address a broad spectrum of p53-related cancers.
In addition to its core focus on p53 mutations, PMV Pharmaceuticals is engaged in expanding its research and development efforts to explore new therapeutic opportunities and enhance its drug discovery platform. The company’s approach combines cutting-edge science with a strategic vision to bring transformative treatments to patients with challenging and underserved cancers. By leveraging advanced technologies and deep expertise in oncology, PMV Pharmaceuticals strives to make a meaningful impact on cancer treatment and patient outcomes.
Originally founded as PJ Pharmaceuticals, Inc., the company rebranded to PMV Pharmaceuticals, Inc. in July 2013. Incorporated in 2013 and headquartered in Cranbury, New Jersey, PMV Pharmaceuticals continues to build on its foundation of scientific excellence and innovation. The company's commitment to precision oncology and its focus on addressing critical genetic mutations underscore its role as a pioneer in the development of targeted cancer therapies.
|
